Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BI 907828 + Ezabenlimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 907828 | BI907828|BI-907828|Brigimadlin | MDM2 Inhibitor 22 | BI 907828 is an MDM2 inhibitor that potentially inhibits tumor growth and improves anti-tumor immunity (PMID: 31201607; Cancer Res 2018;78(13 Suppl):Abstract nr 4866). | |
Ezabenlimab | BI754091|BI-754091|BI 754091 | Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112 | Ezabenlimab (BI 754091) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 wild-type | Advanced Solid Tumor | predicted - sensitive | BI 907828 + Ezabenlimab | Phase I | Actionable | In a Phase I trial, Ezabenlimab (BI 754091) and BI 907828 combination therapy demonstrated safety in patients with TP53 wild-type advanced solid tumors (n=9), and resulted in a partial response (PR) in 2 patients with biliary tract carcinoma, 1 urothelial carcinoma patient, and 1 myxoid liposarcoma patient, an unconfirmed PR in an intrahepatic cholangiocarcinoma patient, and stable disease in 4 patients with liposarcoma or gastric cancer (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3095; NCT03964233). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06084689 | Phase II | BI 907828 + Ezabenlimab | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE) | Not yet recruiting | FRA | 0 |
NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab BI 907828 | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With Ezabenlimab With or Without BI 754111 | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | AUS | 4 |